一个高效的单臂贝叶斯适应性试验算法来评估减强的瘤治疗
Yuan Zhong1, Zeynep Baskurt1, Mahmood Aminilari2
1Biostatistics Department, University Health Network, Toronto, ON, Canada.
Trials
|December 10, 2025
概括
本研究介绍了贝叶斯适应方法用于临床试验设计,提高罕见癌症和减强治疗的效率. 贝叶斯AT R包有助于分析生存数据,并更快地得出治疗疗效的结论.
科学领域:
- 在瘤学瘤学.
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
背景情况:
- 评估减强型瘤治疗可以降低患者的毒性并改善患者的生活质量.
- 在罕见的癌症中存在挑战,因为需要足够的事件数据需要长时间的试验.
- 对于不常见的癌症,传统的随机试验可能是不切实际的,需要采取减强的策略.
研究的目的:
- 为单臂试验设计引入贝叶斯适应方法.
- 能够在具有挑战性的临床试验环境中有效分析生存数据.
- 促进对试验设计和样本大小的确定进行可靠的估计和预测.
主要方法:
- 使用贝叶斯的适应性方法,结合先前的知识和历史的控制武器.
- 使用R包"BayesAT",用于灵活的建模和多阶段的中间分析.
- 设计用于高效的生存数据分析,特别是用于减强的瘤治疗.
主要成果:
- 该方法的有效性通过广泛的模拟研究和灵敏度分析得到证实.
- 成功应用于小儿霍奇金淋巴瘤试验.
- 证明有效地使用事先信息和中间分析来加快结论.
结论:
- 贝叶斯适应方法为临床试验提供了一种高效的方法,该试验具有生存数据限制.
- "BayesAT"套件为实施这种方法提供了一个实用的工具.
- 这种方法加快了关于治疗有效性的结论,特别是对于罕见癌症的减强策略.
更多相关视频
10:13Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
Published on: June 21, 2022
2.6K
06:20Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
7.6K
相关概念视频
Cancer Survival Analysis
629
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
629
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
